ARIZ Announces Grant of Key US Patent
August 20, 2024
DAVIS, CALIFORNIA, UNITED STATES, August 20, 2024 /EINPresswire.com/ — ARIZ Precision Medicine, Inc., a preclinical stage biopharmaceutical company developing precision ligand targeted siRNA cancer therapies, today announced the issuance of a broad patent for a highly specific drug candidate (ARIZ-047) that has been shown to be highly effective in killing lung cancer cells in both cell culture and animal model experiments. US Patent 12,012,597 B2: Cancer Treatment Using siRNA to Modulate Expression of PRDM2/RIZ Protein covers both pharmaceutical compositions and methods for treating a broad range of cancers.